vs
STANDARD BIOTOOLS INC.（LAB）与Precipio, Inc.（PRPO）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是Precipio, Inc.的2.9倍（$19.6M vs $6.8M），Precipio, Inc.净利率更高（7.7% vs -177.4%，领先185.1%），Precipio, Inc.同比增速更快（28.4% vs -11.5%），Precipio, Inc.自由现金流更多（$291.0K vs $-23.1M），过去两年Precipio, Inc.的营收复合增速更高（40.0% vs -12.2%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
Precipio, Inc.是一家专业诊断企业，专注于开发和提供肿瘤学、遗传学及罕见病领域的先进检测解决方案，主要服务美国市场的医疗机构、临床实验室及患者群体，致力于提升诊断准确率，改善患者健康预后。
LAB vs PRPO — 直观对比
营收规模更大
LAB
是对方的2.9倍
$6.8M
营收增速更快
PRPO
高出39.9%
-11.5%
净利率更高
PRPO
高出185.1%
-177.4%
自由现金流更多
PRPO
多$23.4M
$-23.1M
两年增速更快
PRPO
近两年复合增速
-12.2%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $6.8M |
| 净利润 | $-34.7M | $526.0K |
| 毛利率 | 48.5% | 45.9% |
| 营业利润率 | -168.5% | 7.9% |
| 净利率 | -177.4% | 7.7% |
| 营收同比 | -11.5% | 28.4% |
| 净利润同比 | -28.8% | 244.1% |
| 每股收益（稀释后） | $-0.09 | $0.36 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABPRPO
| Q4 25 | — | $6.8M | ||
| Q3 25 | $19.6M | $6.9M | ||
| Q2 25 | $21.8M | $5.6M | ||
| Q1 25 | $40.8M | $4.9M | ||
| Q4 24 | — | $5.3M | ||
| Q3 24 | $22.1M | $5.3M | ||
| Q2 24 | $22.5M | $4.5M | ||
| Q1 24 | $45.5M | $3.5M |
净利润LABPRPO
| Q4 25 | — | $526.0K | ||
| Q3 25 | $-34.7M | $-79.0K | ||
| Q2 25 | $-33.5M | $74.0K | ||
| Q1 25 | $-26.0M | $-884.0K | ||
| Q4 24 | — | $-365.0K | ||
| Q3 24 | $-26.9M | $-626.0K | ||
| Q2 24 | $-45.7M | $-1.2M | ||
| Q1 24 | $-32.2M | $-2.1M |
毛利率LABPRPO
| Q4 25 | — | 45.9% | ||
| Q3 25 | 48.5% | 43.6% | ||
| Q2 25 | 48.8% | 43.2% | ||
| Q1 25 | 48.4% | 43.6% | ||
| Q4 24 | — | 49.8% | ||
| Q3 24 | 54.9% | 43.1% | ||
| Q2 24 | 46.1% | 38.1% | ||
| Q1 24 | 53.1% | 26.5% |
营业利润率LABPRPO
| Q4 25 | — | 7.9% | ||
| Q3 25 | -168.5% | -0.9% | ||
| Q2 25 | -118.1% | -14.6% | ||
| Q1 25 | -80.8% | -17.5% | ||
| Q4 24 | — | -6.3% | ||
| Q3 24 | -120.9% | -11.3% | ||
| Q2 24 | -134.5% | -26.8% | ||
| Q1 24 | -132.2% | -59.6% |
净利率LABPRPO
| Q4 25 | — | 7.7% | ||
| Q3 25 | -177.4% | -1.1% | ||
| Q2 25 | -153.7% | 1.3% | ||
| Q1 25 | -63.8% | -18.0% | ||
| Q4 24 | — | -6.9% | ||
| Q3 24 | -122.0% | -11.9% | ||
| Q2 24 | -203.3% | -27.1% | ||
| Q1 24 | -70.6% | -59.8% |
每股收益（稀释后）LABPRPO
| Q4 25 | — | $0.36 | ||
| Q3 25 | $-0.09 | $-0.05 | ||
| Q2 25 | $-0.09 | $0.05 | ||
| Q1 25 | $-0.07 | $-0.59 | ||
| Q4 24 | — | $-0.22 | ||
| Q3 24 | $-0.07 | $-0.42 | ||
| Q2 24 | $-0.12 | $-0.83 | ||
| Q1 24 | $-0.27 | $-1.46 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | $2.7M |
| 总债务越低越好 | — | $83.0K |
| 股东权益账面价值 | $399.7M | $14.6M |
| 总资产 | $539.6M | $21.3M |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资LABPRPO
| Q4 25 | — | $2.7M | ||
| Q3 25 | $129.4M | $2.3M | ||
| Q2 25 | $158.6M | $1.1M | ||
| Q1 25 | $150.9M | $1.0M | ||
| Q4 24 | — | $1.4M | ||
| Q3 24 | $210.6M | $1.1M | ||
| Q2 24 | $269.8M | $1.3M | ||
| Q1 24 | $287.1M | $776.0K |
总债务LABPRPO
| Q4 25 | — | $83.0K | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $383.0K | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $55.1M | — | ||
| Q1 24 | $55.0M | — |
股东权益LABPRPO
| Q4 25 | — | $14.6M | ||
| Q3 25 | $399.7M | $13.7M | ||
| Q2 25 | $424.5M | $12.3M | ||
| Q1 25 | $454.6M | $11.7M | ||
| Q4 24 | — | $12.1M | ||
| Q3 24 | $489.3M | $11.9M | ||
| Q2 24 | $510.3M | $12.1M | ||
| Q1 24 | $577.3M | $12.8M |
总资产LABPRPO
| Q4 25 | — | $21.3M | ||
| Q3 25 | $539.6M | $21.2M | ||
| Q2 25 | $557.0M | $18.8M | ||
| Q1 25 | $579.6M | $17.8M | ||
| Q4 24 | — | $17.0M | ||
| Q3 24 | $681.5M | $17.0M | ||
| Q2 24 | $708.7M | $17.3M | ||
| Q1 24 | $777.7M | $16.6M |
负债/权益比LABPRPO
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.03× | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $366.0K |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | $291.0K |
| 自由现金流率自由现金流/营收 | -118.1% | 4.3% |
| 资本支出强度资本支出/营收 | 4.5% | 1.1% |
| 现金转化率经营现金流/净利润 | — | 0.70× |
| 过去12个月自由现金流最近4个季度 | $-111.1M | $359.0K |
8季度趋势，按日历期对齐
经营现金流LABPRPO
| Q4 25 | — | $366.0K | ||
| Q3 25 | $-22.2M | $10.0K | ||
| Q2 25 | $-20.7M | $353.0K | ||
| Q1 25 | $-30.3M | $-44.0K | ||
| Q4 24 | — | $565.0K | ||
| Q3 24 | $-27.9M | $41.0K | ||
| Q2 24 | $-39.0M | $500.0K | ||
| Q1 24 | $-62.5M | $-667.0K |
自由现金流LABPRPO
| Q4 25 | — | $291.0K | ||
| Q3 25 | $-23.1M | $-44.0K | ||
| Q2 25 | $-22.6M | $294.0K | ||
| Q1 25 | $-35.3M | $-182.0K | ||
| Q4 24 | — | — | ||
| Q3 24 | $-30.1M | $-68.0K | ||
| Q2 24 | $-41.0M | — | ||
| Q1 24 | $-63.3M | — |
自由现金流率LABPRPO
| Q4 25 | — | 4.3% | ||
| Q3 25 | -118.1% | -0.6% | ||
| Q2 25 | -103.6% | 5.2% | ||
| Q1 25 | -86.6% | -3.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | -136.4% | -1.3% | ||
| Q2 24 | -182.2% | — | ||
| Q1 24 | -138.9% | — |
资本支出强度LABPRPO
| Q4 25 | — | 1.1% | ||
| Q3 25 | 4.5% | 0.8% | ||
| Q2 25 | 8.7% | 1.0% | ||
| Q1 25 | 12.4% | 2.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | 10.2% | 2.1% | ||
| Q2 24 | 8.6% | — | ||
| Q1 24 | 1.7% | — |
现金转化率LABPRPO
| Q4 25 | — | 0.70× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 4.77× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
PRPO
暂无分部数据
